Overview

A Randomized Study to Evaluate the Efficacy of 5-Aza for Post-Remission Therapy of AML in Elderly Patients

Status:
Completed
Trial end date:
2021-09-27
Target enrollment:
Participant gender:
Summary
The present study aims to compare the efficacy of postremission maintenance therapy with 5-Aza versus best supportive care (BSC) in a cohort of AML patients aged >60 years, who have achieved CR following conventional induction ('3+7') and consolidation chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Associazione Qol-one
Treatments:
Azacitidine